Bremelanotide
The labeling file opened for this draft is the VYLEESI prescribing information revised in October 2026.
What the opened sources say
Section titled “What the opened sources say”- The highlights identify VYLEESI (bremelanotide injection), for subcutaneous use, as a melanocortin receptor agonist with initial U.S. approval in 2019.
- The labeled indication is acquired, generalized hypoactive sexual desire disorder in premenopausal women, with low desire that causes marked distress or interpersonal difficulty, and not due to a co-existing medical or psychiatric condition, a relationship problem, or a medication or other drug.
- Limitations of use on the highlights: not indicated for hypoactive sexual desire disorder in postmenopausal women or in men, and not indicated to enhance sexual performance.
- The highlights list uncontrolled hypertension or known cardiovascular disease as a contraindication, and a warning for a transient increase in blood pressure and decrease in heart rate after each dose that usually resolves within 12 hours.
Not stated here
Section titled “Not stated here”The dose, autoinjector steps, and administration timing printed on the label are intentionally not copied.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Regulatory status: VYLEESI (bremelanotide injection) labeling: initial U.S. approval 2019. This page does not evaluate other products sold as PT-141.
Sources
- VYLEESI (bremelanotide injection) prescribing information, revised October 2026 (primary, accessed 2026-11-20)
Referenced by
A link from another wiki page is not evidence. Facts should point at the sources above.